Pharmacological evaluation of selected arylpiperazines with atypical antipsychotic potential

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 16, 2004, Pages 4263-4266

  Tomić, Mirko ^a   Kundaković, Marija ^a   Butorović, Biljana ^a   Janać, Branka ^a   Andrić, Deana ^b   Roglić, Goran ^b   Ignjatović, Djurdjica ^c   Kostić Rajačić, Sladjana ^c  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b Faculty of Biology   (Serbia)

^c Institute for Chemistry   (Serbia)

Author keywords

Arylpiperazine; Atypical antipsychotic; Dopamine receptors; Serotonin receptors

Indexed keywords

5 [2 [4 (2,3 DIMETHYLPHENYL)PIPERAZIN 1 YL]ETHYL] 1H BENZOTRIAZOLE; ALPHA 1 ADRENERGIC RECEPTOR; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DEXAMPHETAMINE; DOPAMINE; PIPERAZINE DERIVATIVE; SEROTONIN; SEROTONIN 1A RECEPTOR; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; BINDING AFFINITY; CONTROLLED STUDY; DRUG POTENCY; LOCOMOTION; NONHUMAN; RAT;

EID: 3142691095     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.06.005     Document Type: Article

References (28)

1. Wiesel F.-A. Br. J. Psychiat. 164:1994;65
2. Sramek J.J., Cutler N.R., Kurtz N.M., Murphy M.F., Carta A. Sramek J.J. Optimizing the Development of Antipsychotic Drugs. 1997;7-99 Wiley, Chichester
3. Joyce J.N., Meador-Woodruff J.H. Neuropsychopharmacology. 16:1997;375
4. Kapur S., Seeman P. Am. J. Psychiatry. 158:2001;360
5. Heresco-Levy U. Prog. Neuropsychopharmacol. 27:2003;1113
6. Bymaster F.P., Felder C.C., Tzavara E., Nomikos G.G., Calligaro D.O., Mckinzie D.L. Prog. Neuropsychopharmacol. 27:2003;1125
7. Svensson T.H. Prog. Neuropsychopharmacol. Biol. Psychiatry. 27:2003;1145
8. Meltzer H.Y. Neuropsychopharmacology. 21:1999;106
9. Meltzer H.Y., Matsubara S., Lee J.C. Psychopharmacol. Bull. 25:1989;390
10. Meltzer H.Y., Li Z., Kaneda Y., Ichikawa J. Prog. Neuropsychopharmacol. 27:2003;1159
11. Ichikawa J., Ishii H., Bonaccorso S., Fowler W.L., O'Laughlin I.A., Meltzer H.Y. J. Neurochem. 76:2001;1521
12. Bantick R.A., Deakin J.F., Grasby P.M. J. Psychopharmacol. 15:2001;37
13. Burris K.D., Molski T.F., Xu C., Ryan E., Tottori K., Kikuchi T., Yocca F.D., Molinoff P.B. J. Pharmacol. Exp. Ther. 302:2002;381
14. Dukić S., Vujović M., Šoškić V., Joksimović J. Arzneimforsch. 47:1997;239
15. Dukić S., Kostić-Rajačić S., Dragović D., Šoškić V., Joksimović J. Pharm. Pharmacol. 49:1997;1036
16. Kostić-Rajačić S., Šoškić V., Joksimović J. Arch. Pharm. (Weinheim). 331:1998;22
17. 1 -adrenergic receptor binding assays
18. Vogel G.H., Vogel W.H. Drug Discovery and Evaluation - Pharmacological Assays. 1997;269-312 Springer-Verlag, Berlin, Heidelberg
19. Tomić M., Kundaković M., Butorović B., Vasilev V., Dragović D., Roglić G., Ignjatović D., Šoš kić V., Kostić-Rajačić S. Pharmazie. 58:2003;677
20. Grunder G., Wetzel H., Hammes E., Benkert O. Psychopharmacology (Berl). 111:1993;123
21. 12 The animals (5-6 per group) were i.p. injected with saline/DMSO, compound 2 (1.0 or 10.0 mg/kg) or haloperidol (1.0 mg/kg). The forepaws were placed on a 10 cm high horizontal bar, while the hind paws remained on the floor. An amount of time spent when at least one forepaw on bar was determined. The animal was considered to be cataleptic if it remained on the bar for at least 60 s. The test was performed 30, 60, 90 and 180 min upon the treatment in three trials. Percentage of cataleptic animals was calculated.
22. Test on open field behaviour: Two series of four and three experimental groups (6-8 animals per group) were i.p. given d-AMPH sulfate (5.0 mg/kg) or physiological saline. Compound 2 was originally dissolved in DMSO (final conc. up to 2%), diluted with saline and i.p. injected 1.0, 3.0 mg (only AMPH group) or 10.0 mg in 2.0 mL volume per kg b.w., 20 min before the d-AMPH (or saline) application; control group received only saline/DMSO. Motor activity in an open field test and stereotypy score were monitored automatically in photo-beam activity cages with a Columbus Auto-Track System (Version 3.0 A, Columbus Institute, OH, USA), starting immediately after the first injection, ending 120 min upon the second treatment. The individual amounts of locomotion (in cm) and stereotypic activities were expressed at successive 10 min (before the second injection) or 20 min periods. All experiments were done on habituated animals (20 min before the first injection). Statistical analysis was performed by nonparametric Kruskal-Wallis test followed by Mann-Witney U-test (Statistica for Windows, 5.0, StatSoft)
23. Towell A., Willner P., Muscat R. Pharmacol. Biochem. Behav. 28:1987;423
24. Ljungberg T., Ungerstedt U. Pharmacol. Biochem. Behav. 23:1985;479
25. Moore S., Kenyon P. Psychopharmacology (Berl). 114:1994;123
26. Robertson A., MacDonald C. Pharmacol. Biochem. Behav. 21:1984;97
27. Tschanz J.T., Rebec G.V. Pharmacol. Biochem. Behav. 31:1988;519
28. Howard H. Exp. Opin. Ther. Patents. 7:1997;353